Skip to main content

Schizophrenia & Psychotic Disorders

Patients who switched from risperidone to lurasidone experienced reductions in several adverse effects, proportionate to increases experienced while on risperidone, according to a study in BMC Psychiatry.
Patients with an acute exacerbation of schizophrenia who received an investigational antipsychotic drug had significantly greater improvement in the PANSS total score, compared with those who received placebo, according to a published study.
An analysis of brain scans from more than 300 patients suggests two distinct neuroanatomical subtypes of schizophrenia. Researchers published the findings online in the journal Brain.
In this video, Christoph U. Correll, MD, of Hofstra/Northwell in New York, discusses the possible clinical applications of the combination of olanzapine and the mu-opioid antagonist samidorphan.
Christoph U. Correll, MD, discusses the results of the ENLIGHTEN‑2 study, which compared weight gain and cardiometabolic side effects in patients taking olanzapine and patients taking olanzapine plus samidorphan.
In this video, Christoph U. Correll, MD, of Hofstra/Northwell in New York, discusses the possible clinical applications of the combination of olanzapine and the mu-opioid antagonist samidorphan.
What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications? 
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top